 Abstract the IAS gene is one of the most frequently mutated genes in cancer, making it an attractive target for drug discovery. Recently, a CRAS G12C inhibitor was developed which has shown promising results in treating various types of cancer. This review summarizes the structural and biochemical properties of different IAS mutations, their pathological characteristics, and the development of IAS targeting drugs. The hope is to provide a better understanding of how these mutations affect the disease progression and to identify potential targets for future drug development. This article was authored by Centelieu, Danyang Yi, Hong Liu Yang, and others.